ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Apr 22, 2024--
Source: eagletribune.com
Mitchell Finer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mitchell Finer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mitchell Finer Today - Breaking & Trending Today
Novo Nordisk strikes potential $2B-plus gene editing deal with Durham's Life Edit
Gene editing from a Durham-based firm that will target possible new therapeutics has led to a deal with international drug firm Novo Nordisk worth a potential $2 billion if not more. Here are the details.
Source: wraltechwire.com
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing ...
Source: pharmiweb.com
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies
Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing life-changing therapies for rare genetic disorders as well as more prevalent cardiometabolic diseases.
Source: sciencebusiness.net
Novo Nordisk A/S: Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global
Source: finanznachrichten.de